Skip to main content
. 2024 Mar 27;15:2691. doi: 10.1038/s41467-024-46961-x

Fig. 2. Median invasive disease-free survival (iDFS) and overall survival (OS).

Fig. 2

iDFS (A) and OS (B) stratified by treatment arm. iDFS (C) and OS (D) stratified by the presence or absence of circulating tumor DNA (ctDNA) at landmark in patients enrolled in Arms A, B, and C combined. Blue line: Arm A (nivolumab); Red line: arm B (capecitabine); Green line: Arm C (combination of nivolumab and capecitabine). Source data are provided as a source data file.